Hyperbaric oxygen in the treatment of calciphylaxis: A case series and literature review

Jennifer An1, Bridget Devaney2, Khai Yang Ooi1

  • 1Department Renal Medicine, Alfred Hospital, Melbourne, Victoria, Australia.

Nephrology (Carlton, Vic.)
|February 25, 2015
PubMed

Insights

Hyperbaric oxygen therapy (HBOT) shows promise for treating calcific uraemic arteriolopathy (CUA), also known as calciphylaxis. Over half of patients receiving HBOT experienced wound healing and improved survival, with diabetes being a key predictive factor.

Area of Science:

  • Nephrology
  • Dermatology
  • Vascular Surgery

Background:

  • Calcific uraemic arteriolopathy (CUA), or calciphylaxis, is a severe condition often seen in end-stage renal disease patients.
  • CUA is characterized by significant morbidity and mortality, posing a challenge in treatment.
  • Identifying effective therapies for CUA is crucial for improving patient outcomes.

Purpose of the Study:

  • To evaluate the efficacy of hyperbaric oxygen therapy (HBOT) in healing CUA lesions.
  • To identify patient-specific factors that predict wound healing and survival in CUA patients treated with HBOT.

Main Methods:

  • Retrospective review of CUA patients treated with HBOT at the institution.
  • Documentation of clinical and biochemical parameters, lesion characteristics, wound outcomes, and survival.
  • Analysis of patient data to determine factors associated with treatment success.

Main Results:

  • 46 patients with renal failure-associated CUA were identified; 34 completed HBOT.
  • 58% of patients receiving HBOT showed wound improvement, with over half achieving complete healing.
  • Patients benefiting from HBOT survived over 3 years on average; diabetes was linked to better outcomes.

Conclusions:

  • HBOT appears to be a beneficial treatment for CUA, improving wound healing and survival rates.
  • More than half of patients undergoing HBOT experienced positive outcomes, including extended survival.
  • Diabetes emerged as a significant predictor of improved wound healing and survival in CUA patients treated with HBOT.
Abstract

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure01:16

Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure

Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
804
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
623
Hypoxia01:23

Hypoxia

Hypoxia is a medical condition characterized by an inadequate oxygen supply to body tissues. It typically manifests as a bluish discoloration of the skin and mucosae, especially in fair-skinned individuals, when hemoglobin (Hb) saturation drops below 75%.
Types of Hypoxia
There are four primary types of hypoxia, each resulting from a different cause:
1. Anemic hypoxia: This type occurs due to insufficient oxygen delivery caused by a lack of red blood cells (RBCs) or RBCs with abnormal or...
2.7K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
667
Pneumothorax-II01:27

Pneumothorax-II

Pneumothorax is a medical condition defined by the buildup of air in the pleural space between the lungs and the chest wall. This accumulation of air can lead to partial or complete lung collapse, resulting in a range of clinical manifestations. Understanding the clinical presentation and effective management strategies is crucial for healthcare professionals in providing timely and appropriate care to individuals with pneumothorax.
Clinical Manifestations:
1.5K
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
473